Focus on:  Hide Contributions
Back to Conference View
Login

MEDAMI 2017 - V MEDITERRANEAN FORUM ON ADVANCED MOLECULAR IMAGING

→ Europe/Rome
Orosei

Orosei

Sardinia
Description
                                
                      ______________________________________________________________________

                                     MULTIMODALITY AND MULTIPARAMETRIC IMAGING
                                                          IN ADVANCING HEALTHCARE
                                                TOWARDS PERSONALIZED MEDICINE
                      ______________________________________________________________________
                      





Following the  previously conducted symposia on dedicated medical imaging instrumentation we are presently organizing the 5th workshop of this exclusive series to be held in the East of the beautiful island of Sardinia.
The purpose of this meeting is to discuss the role of the multimodality and multi-parametric imaging modalities on the vision of individualized/personalized medicine.
Based on the breakthroughs in genomic, proteomic and metabolic profiling Precision Medicine has emerged as a novel health-care paradigm. Precision Medicine is an approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle. It involves integrating information from multiple sources to achieve a precise diagnosis, personalized target treatment, and adequate response assessment.
The “-omics” analysis as well as histopathology are important input parameters for a precise diagnosis, however, as they rely on small biopsy samples or body fluids, they do usually not map the entire profile of the disease. Tumors typically have a spatially and temporally varying molecular and genetic profile; the same applies to neurodegenerative, cardiovascular or autoimmune diseases. Therefore, “liquid diagnostic parameters” can provide only a snapshot of the entire disease while Multiparametric Imaging can holistically map molecular, functional and habitant varieties of the same or multiple diseases.
Thus, Multiparametric Imaging and Imaging-Guided Interventions, which provide multiparametric information and enable focused, minimally invasive treatments, are key elements of complex Precision Diagnosis and Personalized Medicine. Different diagnostic approaches utilizing bioinformatics, machine learning, and systems biology will be used to mine the essential information and fuse the precise but spatially and temporally restricted disease characterization of “-omics” and histopathology with the holistic data of Multiparametric Imaging. The emerging fields of Radiomics and Radiogenomics are linking genotypic information to phenotypic disease manifestations from imaging. Because of the growing volume and complexity of imaging data and its necessary linkage to metadata, decision-support algorithms will be required to help physicians applying the most essential patient data for optimal management.
Based on the above emerging realities the MEDAMI Forum series of events is trying to define the role of and needs for Multiparametric Imaging in the development of healthcare towards Personalized/Precision Medicine and to determine the impact of those developments on collaboration- and business models in the future.
 
What are the key questions the MEDAMI 2017 will address?
 

 

  • Personalized Medicine – what will be the impact of what? on current medical imaging and image guided interventions? Is there a need for organ specific (precision) medical imaging?
  • Which  medical areas  have the  the strongest impact/needs?
  • Are there new imaging technologies and methods for precision imaging?
  • In which areas are new biomarkers and imaging agents  needed? What shall be the role of such new tracers and imaging agents in personalized medical imaging?
  • What funding mechanisms can be employed for the development of imagers and imaging agents that finally lead to widespread clinical application? What are the roles of funding agencies and industry?
  • How does Personalized Medicine impact the business models of stakeholders (industries, clinics, health care providers)?

 
The program of the MEDAMI 2017 is being developed . A number of Key Opinion Leaders (KOL’s) from Biology, Medicine and Technology fields have already been contacted to give lectures.

The program of the forum primarily will consist of invited talks by key opinion leaders and experts from around the world. However, a limited number of abstracts for oral or poster presentations will be accepted. If you have to report on a topic that you think fits into the scope of the program we will be happy to receive your abstract.

Preliminary list of key speakers who accepted to come and talk:
  - Prof. Roderic Pettigrew, director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB)- USA 
  - Prof. David Townsend, National University of Singapore, inventor of PET/CT 
  - Prof. Craig Levin, Stanford Molecular Imaging Instrumentation Laboratory (MIIL) – USA 
  - Prof. Bernd Pichler, University of Tubingen (Germany) 
The meeting format fosters a close interaction between different stakeholders from academia, medical institutions and organizations, regulatory agencies and industry.

Technical secretary:
Maurizio Lucentini, Sabina Pellizzoni,
Michela Giovagnoli, Alessandro Spurio
Tel: 06 4990 2232
maurizio.lucentini@iss.infn.it

      webmaster: Alessandro Spurio, Maurizio  Lucentini   -   webdesigner: Alessandro Spurio (2017)

 

                

            
       

==============================================================================
with support from


             
       Risultati immagini per siemens 

       

 

 

 

Participants
  • AKIO KIDO
  • Alberto Del Guerra
  • Alberto Masoni
  • Bernd Pichler
  • Bernd Stowasser
  • Bipin Singh
  • Charles Guttmann
  • Christer Halldin
  • CLAUDIO PIEMONTE
  • Constantin Lapa
  • David Townsend
  • Dennis Schaart
  • ELENA SOLFAROLI CAMILLOCCI
  • Eugenii Rabiner
  • Fijs van leeuwen
  • Fortunato Cirillo
  • Francesca Garibaldi
  • Francesco Pennazio
  • FRANCO Garibaldi
  • Gabriela Llosá
  • Guennadi Jogolev
  • Heather Nugent
  • henk van der poel
  • Ilaria Mattei
  • Jonathan Disselhorst
  • José María Benlloch Baviera
  • Juan Nikandi Salinas González
  • Manuela Cirilli
  • Marco Paganoni
  • Markus Ehrenfried
  • Martin Walter
  • Maurizio Conti
  • Maurizio Conti
  • Maurizio Lucentini
  • Michel Herranz
  • Michela Giovagnoli
  • Michele Bailey
  • Nicholas Petrick
  • Nicoletta Protti
  • Orazio Schillaci
  • Paul Lecoq
  • Paul Matthews
  • Piergiorgio Cerello
  • Piotr Maniawski
  • Roderic Pettigrew
  • sabina pellizzoni
  • Simone Sarasso
  • Stan Majewski
  • Stefaan Tavernier
  • TERRY JONES
  • Tobias Maurer
  • Valentina Garibotto
  • Valeria Panebianco
  • Vesna Sossi
  • Volkmar Schulz
  • York Hämisch
  • Wednesday, 31 May
    • Welcome addresses
    • Session 1.1: Introductory Session (Moderator: Franco Garibaldi)
    • 10:10
      Coffee break
    • Session 1.2: Research concepts/activities (Moderator: York Haemisch)
      • 3
        Piotr Maniawski (Philips Healthcare, on behalf of the Association of Imaging Producers and Equipment Suppliers (AIPES)) - The AIPES organization and its role in supporting medical imaging development
        Abstract
      • 4
        Marco Paganoni (Univ. of Milano) - ERAMIT
        Abstract
      • 5
        Maurizio Conti (Siemens Healthineers, Knoxville) - Challenges and trends in molecular imaging, an industry research viewpoint. The role of radiotracers in modern diagnosis and expensive/advanced therapies
    • 12:00
      Lunch break
    • Poster Session
    • Session 1.3: Diagnostic Imaging, theranostics and the -omics (Moderators: Bernd Pichler, Jonathan Disselhorst)
      • 6
        David Townsend (National University of Singapore) - PET/CT, PET/MR and Precision Medicine: some alternative facts
      • 7
        Bernd Pichler (Dept. of Pre-clinical imaging and Radiopharmacy University of Tuebingen) - Combining multiparametric imaging data with –omics information for precision medicine
      • 8
        Constantin Lapa (Nuclear Medicine, University of Wurzburg) - Theranostics and multimodality imaging
        Abstract
    • 16:15
      Coffee break
    • Session 1.3 (cont)
      • 9
        Jonathan A. Disselhorst (University Tuebingen) - Imaging Tumor Heterogeneity
        Abstract
      • 10
        P. Pevsner - How cost-effectiveness of a diagnostic medical imaging procedure is determined
      • 11
        Roderic Pettigrew (Director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB)) - Multimodality/Multiparametric Imaging and Precision Medicine
    • ROUND TABLE - The relation of academia and industry in the development of medical and molecular imaging technologies. Chair: Paul. Lecoq, CERN - Representatives of funding institutions, industries, MDs, physicists/technologists Outcome: proposals for improvement of academia-industry relation
  • Thursday, 1 June
    • Session 2.1: Neurodegenerative diseases and brain disorders
      • 12
        Charles R.G. Guttman (Center for Neurological Imaging, Harvard Medical School) - Neurodegenerative diseases - an overview
        Abstract
      • 13
        Valentina Garibotto (Univ.of Geneva) - Multimodal/multiparamenter imaging – main modalities and applications: link to biomarkers and personalized medicine
        Abstract
        Slides
      • 14
        Martin Walter (University of Tuebingen, Germany) -Multimodal imaging in psychiatry
      • 15
        Vesna Sossi (University of British Columbia) - PET/MRI imaging in neurodegeneration: novel metrics for early disease detection and effect of therapy assessment
        Abstract
    • 10:30
      Lunch break
    • Session 2.2: Brain biomarkers and brain imaging initiatives
      • 16
        Christer Halldin (Karolinska Institutet, Stockholm) - PET Radioligands for Neuroscience and Drug Development
        Abstract
        Slides
      • 17
        Ilan Rabiner (Chief Medical Officer, Head of Imaging Applications, Imanova Ltd., UK) - Building the Three Pillars- Imaging in early phase drug development
        Abstract
      • 18
        Paul M. Matthews (Head of Brain Imaging Sciences, Imperial College, London) - Challenges and opportunities for brain imaging with large population datasets
        Abstract
      • 19
        Simone Sarasso (Dept. of Biomedical Sciences, University of Milano) - Major brain initiatives
    • 13:00
      Lunch break
    • Poster Session
    • Session 2.3: Brain imaging - new technologies
      • 20
        Stan Majewski (University of Virginia) - Dedicated PET brain imaging devices
        Abstract
      • 21
        Bernd Pichler (Director, Dept. of Pre-clinical imaging and Radiopharmacy, University of Tuebingen) - Developments in MRI, MEG and EEG
    • 16:50
      Coffee break
    • Session 2.3: Brain imaging - new technologies
      • 22
        Jose Maria Benlloch (Institute of Molecular Imaging, University of Valencia) - Mindview: multimodal imaging of neurological disorders
      • 23
        Alberto del Guerra (Department of Physics, University of Pisa) - A trimodality (EEG/MR/PET) scanner for brain imaging
        Abstract
        Slides
      • 24
        Contributions
    • ROUND TABLE - Molecular imaging and -omics: competition or complementarity for Precision medicine? Chair: Vesna Sossi, UBC, Vancouver Representatives of funding institutions, industries, MDs, physicists/technologists
  • Friday, 2 June
    • Session 3.1: New Technologies for Molecular Imaging
      • 25
        Paul Lecoq (CERN, Geneva) - The 10 ps TOF-PET challenge
      • 26
        Dennis Schaart (Department of Rad. Science & Technology, TU Delft) - Fundamentals of Ultrafast Timing
        Abstract
      • 27
        Terry Jones (UCL, London) - The Explorer project: a new paradigm in nuclear medicine?
        Abstract
      • 28
        Piotr Maniawski (Philips Healthcare, Cleveland) - Digital Photon Counting PET: technology powering precision molecular imaging
        Abstract
    • 10:25
      Coffee break
    • Session 3.1 (cont)
      • 29
        Bipin Singh (RMD Watertown, Ma) - Photonic Crystal Enhances Scintillation Light Extraction: Can It Improve Timing Resolution?
        Abstract
        Slides
      • 30
        Claudio Piemonte (FBK Trento) - New high performance SiPM arrays with TSV technology for TOF and other applications
      • 31
        Stefaan Tavernier (PETsys Electronics SA, Lisbon) - TOFPET II: The next generation ASIC for TOF-applications
        Abstract
      • 32
        Gabriela Llosa (Instituto de Fisica Corpuscular, University of Valencia) - From MACACO to MACACO II: a Compton telescope for hadron therapy treatment monitoring
        Abstract
        Slides
      • 33
        Ilaria Mattei (INFN Milano) - Characterisation of the secondary fast and ultrafast neutrons emitted in Particle Therapy with the MONDO experiment
        Abstract
    • 12:40
      Lunch break
    • Poster Session
    • Session 3.2: Molecular Imaging in the diagnosis, treatment and follow up of breast cancer
      • 34
        Orazio Schillaci (TOV Policlinico Tor Vergata, Roma) - The role of Nuclear Medicine in breast cancer management
        Abstract
      • 35
        Michael O’ Connor (Mayo Clinic Rochester) - Breast cancer screening with single gamma and positron emitters
    • 16:30
      Coffee break
    • Poster Session
    • Session 3.3: Technologies for breast imaging/diagnosis
      • 36
        Evaristo Cisbani (ISS and INFN, Roma) - A novel SPECT-Thomosynthesis detector for the diagnosis and follow up of breast cancer
      • 37
        Michel Herranz (Univ. of Santiago de Compostela) - Dedicated breast PET (dbPET) in diagnosis and follow up of breast cancer - comparison, synergies and divergences with MRI
      • 38
        Volkmar Schulz (University of Aachen, DE) - PET-MR dedicated detector for breast cancer diagnosis and follow – up
        Abstract
    • ROUND TABLE - Multimodality multiparametric imaging in cancer management: How can it be improved? (Chair: David Townsend, Singapore)
  • Saturday, 3 June
    • Session 4.1: Molecular Imaging in the management of prostate cancer
      • 39
        H. Van der Pohel (Amsterdam, Ne) - Multimodality imaging in surgery
        Abstract
      • 40
        Tobias Maurer (Klinikum rechts der Isar, TU Munich) - Shifting gears in Imaging - how PSMA-PET is about to change prostate cancer diagnosis
        Abstract
      • 41
        Valeria Panebianco (Università degli Studi di Roma La Sapienza) - The role of multiparametric MR in the diagnosis and follow up of prostate cancer
      • 42
        Paul Lecoq (CERN, Geneva) - ENDO-TOF-PET-US in the diagnosis and follow up of prostate cancer
    • 09:40
      Coffee break
    • Session 4.1: Molecular Imaging in the management of prostate cancer
      • 43
        Franco Garibaldi (AIB, Roma) - TOF-PET-MR in the diagnosis and follow up of the prostate cancer
      • 44
        Nicoletta Protti (INFN Pavia) - In vivo 10B imaging and dose rate measurement for Boron Neutron Capture Therapy (BNCT) using Single Photon Emission Computed Tomography (BNCT-SPECT)
        Abstract
    • Conference Excursion
    • Conference Dinner
  • Sunday, 4 June
    • Session 5.1: Molecular Imaging in surgical interventions
      • 45
        Fijs van Leuven (LUMC, Leiden) - Multimodality imaging techniques in surgery
        Slides
      • 46
        Tobias Maurer (Klinikum rechts der Isar, TU Munich) - PSMA radioguided surgery – a novel technique for intraoperative detection of prostate cancer metastases
      • 47
        Elena Solfaroli (Università degli Studi di Roma La Sapienza) - Radioguided surgery with beta-radiation: test on ex-vivo specimen
        Abstract
        Slides
      • 48
        Image guided robotic surgery in lung cancer. (... to be decided)
    • 09:25
      Coffee break
    • Session 5.2: Molecular Imaging in Hadron Therapy Monitoring
      • 49
        P. Cerello (INFN Torino) - Imaging in hadron therapy
        Abstract
      • 50
        F. Pennazio, INFN Torino) - The INSIDE project: hadron therapy monitoring with in-beam PET
        Abstract
        Slides
      • 51
        Ilaria Mattei (INFN Milano) - Study of the radiation produced by therapeutic He, C and O ion beams impinging on a PMMA target for beam range monitoring purpose in Particle Therapy
        Abstract
    • Closing remarks (TBD)
    • Departure (first bus leaves)
Powered by Indico v3.3.3